$OGN

Drinane Juliana Papa (Head of Mfg & Supply) sold 14,761 shares of Organon & Co. (OGN) at $13.57 ($0.20M total) on 2026-08-05.

Organon & Co. (OGN) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001821825 0001821825 2026-07-23 2026-07-23 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23,

OTC Markets Group said Orogen Royalties Inc (TSX-V: OGN, OTCQX: OGNNF) qualified to trade on OTCQX Best Market, upgrading from OTCQB. It will trade on OTCQX under symbol OGNNF, with U.S. investors able to access disclosures and Level 2 quotes on OTCMarkets.com. Orogen focuses on precious and base metal royalties in North America.

Organon & Co. (OGN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. false 0001821825 0001821825 2026-06-09 2026-06-09 iso4217:USD xbrli:shares iso4217:USD xbrli:shares UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Repor

Hanmi Pharmaceutical has announced a partnership with Organon to export three of its combination therapies for cardiovascular and respiratory conditions to Malaysia and the Philippines. This agreement strengthens Hanmi's presence in the rapidly growing Southeast Asian pharmaceutical market, with Organon handling marketing, distribution, and sales. Both companies aim to expand treatment options and improve access to medicines in the region.

Organon (NYSE:OGN) reported a miss on Wall Street's revenue and earnings expectations for Q1 CY2026, with sales declining 3.5% year-on-year to $1.46 billion and adjusted EPS coming in 16.8% below consensus at $0.71. The company has shown a struggle with consistent revenue growth and decreasing profitability over the past several years. Analysts anticipate revenue to remain flat and full-year EPS to grow marginally in the next 12 months, highlighting ongoing challenges for the pharmaceutical firm.

Organon & Co. (OGN) reported a first-quarter profit of $146 million, with net income of 55 cents per share. Adjusted earnings were 71 cents per share, falling short of Wall Street's expectation of 83 cents per share. The pharmaceutical company's revenue of $1.46 billion also missed analyst forecasts of $1.47 billion.

Sun Pharmaceutical Industries Limited has revealed its definitive agreement to acquire Organon & Co. for US$14.00 per share in an all-cash transaction, valuing Organon at an enterprise valuation of US$11.75 billion. This acquisition is poised to make Sun Pharma a stronger player in established brands/branded generics and a top-10 global player in biosimilars, significantly expanding its global footprint and enhancing its innovative medicines business. The transaction, approved by both companies' boards, is expected to close in early 2027, transforming Sun Pharma into one of the top 25 global pharmaceutical companies with combined revenues of US$12.4 billion.

Organon (OGN) shares surged significantly after reports emerged of a potential $10-12 billion buyout offer from Sun Pharmaceutical Industries. This interest highlights the strategic value of Organon's portfolio in women's health, biosimilars, and established medicines, positioning it as an attractive acquisition target for companies seeking to expand in these areas. The market's reaction suggests a focus on the company's long-term strategic potential rather than its immediate financial profile.

Sun Pharmaceutical Industries Limited shares dropped nearly 4% after reports indicated the company is proceeding with a binding $12 billion offer for Organon & Co. Sun Pharma has reportedly completed due diligence and is finalizing financing for the bid. This potential acquisition could mark the largest global M&A deal involving an Indian pharmaceutical company.